Literature DB >> 15797497

Suspected disk space infection with negative microbiological tests-report of eight cases and comparison with documented pyogenic discitis.

Jérôme Gillard1, David Boutoille, Stéphane Varin, Nathalie Asseray, Jean-Marie Berthelot, Yves Maugars.   

Abstract

UNLABELLED: Few data are available on patients with suspected noniatrogenic pyogenic discitis but negative microbiological tests.
OBJECTIVES: To compare the features, treatment, and outcomes in patients with suspected versus microbiologically documented noniatrogenic pyogenic discitis. PATIENTS: A retrospective chart review identified eight patients with suspected noniatrogenic pyogenic discitis managed at our institution over a 15-year period. Eighteen age- and sex-matched patients with microbiologically documented noniatrogenic pyogenic discitis managed at our institution during the same period served as controls.
RESULTS: The eight cases had a longer time to diagnosis, a greater risk of abscess formation or epidural infection, and a smaller number of cutaneous portals of entry, as compared to the controls. None of the cases had evidence of endocarditis or diabetes mellitus. Infection at another site preceded the discitis in half the cases. Empirical treatment with two antimicrobials (usually a fluoroquinolone with a beta-lactam or fosfomycin) ensured a full recovery in all eight cases, with no relapses or long-term recurrences, whereas relapses occurred in three of the 18 controls treated with antibiotics selected by antibiotic susceptibility testing.
CONCLUSION: Noniatrogenic pyogenic discitis with negative microbiological studies is associated with distinctive clinical features consistent with smoldering infection. The outcome is favorable under empirical two-drug antimicrobial therapy, usually including a fluoroquinolone given by the intravenous route.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15797497     DOI: 10.1016/j.jbspin.2004.01.009

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  8 in total

1.  Clinical features of septic discitis in the UK: a retrospective case ascertainment study and review of management recommendations.

Authors:  Neil Hopkinson; Kamal Patel
Journal:  Rheumatol Int       Date:  2016-07-14       Impact factor: 2.631

2.  Low back pain in a diabetic on chronic haemodialysis: pyogenic spondylodiscitis.

Authors:  Kanterpersad Ramcharan; Liane Conyette; Boris Mohammed; Ravi Narine
Journal:  BMJ Case Rep       Date:  2014-04-30

3.  Diagnostic yield of repeat CT-guided biopsy for suspected infectious spondylodiscitis.

Authors:  Gregory J Czuczman; Daniel E Marrero; Ambrose J Huang; Jacob C Mandell; Varand Ghazikhanian; F Joseph Simeone
Journal:  Skeletal Radiol       Date:  2018-05-18       Impact factor: 2.199

Review 4.  Pyogenic Vertebral Osteomyelitis: Clinical Features, Diagnosis, and Treatment.

Authors:  Ji-Woong Kwon; Seung-Jae Hyun; Sang-Hyun Han; Ki-Jeong Kim; Tae-Ahn Jahng
Journal:  Korean J Spine       Date:  2017-06-30

5.  Delayed Spondylodiscitis Presenting as a Skip Lesion.

Authors:  Dong Min Kim; Seok Won Kim
Journal:  Korean J Spine       Date:  2017-03-31

6.  Bacteriological features of infectious spondylodiscitis at Mohammed V Military Teaching Hospital of Rabat.

Authors:  A Zohoun; E Ngoh Akwa; M El Ochi; N Oragwu; A Akhaddar; A Albouzidi; M El Ouennass
Journal:  Braz J Microbiol       Date:  2012-06-01       Impact factor: 2.476

7.  Diagnostic yield of computed tomography-guided bone biopsy and clinical outcomes of tuberculous and pyogenic spondylitis.

Authors:  Eun-Jeong Joo; Joon-Sup Yeom; Young Eun Ha; So Yeon Park; Chong-Suh Lee; Eun-Sang Kim; Cheol-In Kang; Doo-Ryeon Chung; Jae-Hoon Song; Kyong Ran Peck
Journal:  Korean J Intern Med       Date:  2016-04-15       Impact factor: 2.884

8.  A rare lumbar pyogenic spondylodiscitis caused by staphylococcus caprae with initial misdiagnosis: case report and literature review.

Authors:  Zihan Fan; Yong Yang; Dong Li; Qi Fei
Journal:  BMC Surg       Date:  2020-09-14       Impact factor: 2.102

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.